(AOF) – Sensorion (+5.83% to 0.92 euros) is up after announcing positive results for its Sens-401 product. The clinical-stage biotech specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, has achieved the primary endpoint of its Phase 2a proof-of-concept (POC) clinical trial of Sens-401 for preservation of residual hearing after cochlear implantation. This Phase 2a study is a multicenter, randomized, controlled, open-label trial.
The trial aims to evaluate the presence of Sens-401 in the cochlea (perilymph) at therapeutic levels after 7 days of twice-daily oral administration prior to cochlear implantation due to moderately severe to profound hearing loss. Patients began treatment seven days before implantation and continued to receive the product for an additional forty-two days.
The study is now complete, follow-up of the last patients is still ongoing and secondary endpoints including the results on the preservation of residual hearing will be available and analyzed later in the year.
Sensorion plans to publish the full results of the study during the third half of 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.